Skin rash associated with prolonged progression-free (median, 22.4 vs 10.5 months) and overall (median, 42.6 vs 24.6 months) survival compared with no rash, respectively. Skin rash during ...

Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose ...

The "Cutaneous T-cell lymphoma - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights about 25+ companies and 30+ ...

Nov. 21, 2024 — Hidradenitis suppurativa (HS) is an immune disease that affects up to 4% of the global population and causes painful, recurring skin lesions and inflammation, primarily in the ...

Lenalidomide, an analog of thalidomide, was developed because of its more potent anti-MM activity and better toxicity profile than the parent compound. Since its introduction in 2004, lenalidomide ...

Lumps can form under the skin for many reasons, including cysts or swollen lymph nodes. Often they don’t require treatment, but if they change in size or appearance, contact a doctor for an exam.

Items that we touch or use on our skin every day could affect our health by changing our skin microbiome and making us more or less susceptible to chronic diseases. What exactly a healthy skin ...

What are skin pigment disorders? Skin color is determined by a pigment (melanin) made by specialized cells in the skin (melanocytes). The amount and type of melanin determines a person's skin color.

Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.

Skin inflammation is a sign of an immune response in the body. Symptoms include discoloration (a change in skin tone), heat, swelling, pain, and itching. Skin inflammation has many potential causes, ...

Lenalidomide is also given to the patient as ... closely for the development of any infections and cancers such as skin cancer or any solid tumor as elotuzumab may increase the risk of developing ...